ORCHPHARMA NSE filing

Orchid Pharma Q2 FY27 Investor Presentation: Standalone PAT ₹37 Cr, Revenue ₹341 Cr

The RealCase readHigh impact Positive

Orchid Pharma reported Q2 FY27 standalone revenue of ₹341 Cr, up 14% YoY. PAT surged to ₹37 Cr from ₹7 Cr. H1 FY27 revenue reached ₹645 Cr, with PAT at ₹49 Cr. The company signed licensing deals for EXBLIFEP in Russia and Latin America, estimated at US$ 258 million.

Why it matters

The strong financial performance, coupled with significant strategic partnerships and the ongoing amalgamation, are material developments that are likely to have a substantial impact on the company's valuation and future growth trajectory.

The market read

The company reported significant year-on-year growth in revenue and profit for Q2 FY27, along with improved margins. Strategic partnerships for EXBLIFEP also indicate positive future growth prospects.

Orchid Pharma Limited has released its investor presentation for the second quarter of the financial year 2026-27, which ended on September 30, 2026. The company has scheduled an Analysts/Investors Earning Call on November 17, 2026, at 04:30 PM (IST) to discuss its financial performance.

The standalone financial results for Q2 FY27 show a Revenue from Operations of ₹341 crore, a 14% increase from ₹298 crore in Q2 FY26. Other Income was ₹29 crore, up 76% from ₹16 crore year-on-year. EBITDA surged by 148% to ₹52 crore from ₹20 crore in the same period, with the EBITDA margin improving to 15% from 7% in Q2 FY26. Profit After Tax (PAT) stood at ₹37 crore, a significant increase from ₹7 crore in Q2 FY26. The Gross Margin also improved to 21% in Q2 FY27 from 9% in Q2 FY26.

For the first half of FY27 (H1 FY27), standalone Revenue from Operations increased by 15% to ₹645 crore from ₹562 crore in H1 FY26. EBITDA grew by 151% to ₹77 crore from ₹31 crore, and PAT rose to ₹49 crore from ₹5 crore in H1 FY26. The EBITDA margin for H1 FY27 was 12%, up from 5% in H1 FY26, and the Gross Margin improved to 23% from 17%.

The consolidated financial performance for Q2 FY27 reported Revenue from Operations of ₹341.27 crore, with PAT at ₹28.59 crore. For H1 FY27, consolidated Revenue from Operations was ₹645.44 crore, and PAT was ₹31.82 crore. The consolidated balance sheet as of September 30, 2026, shows total assets of ₹2,652 crore and total equity of ₹1,632 crore, with net debt at ₹487 crore.

Key strategic initiatives include the amalgamation of Dhanuka Laboratories Ltd. into Orchid Pharma Ltd., effective July 10, 2026, which aims to create a unified entity. The company has also signed licensing partnerships for its product EXBLIFEP in Russia with Pharmasyntez, with an estimated sales potential of US$ 178 million, and in Latin America with Laboratorio Libra, with an estimated sales potential of US$ 80 million, covering 9 markets. Combined, these partnerships represent an estimated US$ 258 million across 10 markets.

Filing to action

What to do with a filing like this

Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.

View original filing